NGM Biopharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

NGM Biopharmaceuticals

03/08/2023 22:35

* NGM Biopharmaceuticals Inc  NGM.OQ  reported a quarterly
adjusted loss of 46 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 50 cents per share.
    * Revenue fell 82.8% to $1.42 million from a year ago;
analysts
expected $3.30 million. 
    * NGM Biopharmaceuticals Inc's reported EPS for the quarter
was a
loss of 46 cents​.
    * The mean earnings estimate of analysts had risen by
about 3.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * NGM Biopharmaceuticals Inc shares had fallen by 17.4% this
quarter and lost 57.4% so far this year.
    * The company reported a quarterly loss of $38.26 million.
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $6.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 09:34 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.50          -0.46          Beat
 Mar. 31 2023      -0.52          -0.58          Missed
 Dec. 31 2022      -0.51          -0.45          Beat
 Sep. 30 2022      -0.59          -0.59          Met